LAVA Therapeutics and The Antibody Society Present Emerging Cancer Therapies Virtual Symposium
November 11, 2021 10:08 ET
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA and FRAMINGHAM, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company, today announced that...
LAVA Therapeutics Expands Management Team with Three Key Appointments
November 09, 2021 06:30 ET
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary...
LAVA Therapeutics to Participate in the 12th Annual Jefferies London Healthcare Conference
November 04, 2021 07:00 ET
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Nov. 04, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary...
Stingthera, Inc. Announces Clinical Collaboration with Merck to Evaluate SNX281 in Combination With KEYTRUDA® (pembrolizumab) in Certain Patients with Advanced Solid Tumors and Lymphoma
November 03, 2021 06:45 ET
|
Stingthera, Inc.
BOSTON, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Stingthera, Inc. today announced it has entered into a clinical trial collaboration agreement with Merck (known as MSD outside the United States and Canada)...
LAVA Therapeutics Announces Participation at Upcoming Scientific Conferences
November 02, 2021 07:00 ET
|
Lava Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Nov. 02, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary...
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE BREAST CANCER PARTNERSHIP RECEIVES NATIONAL ACCREDITATION
October 21, 2021 15:23 ET
|
Florida Cancer Specialists & Research Institute
Davenport, Fla., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute (FCS), in collaboration with AdventHealth Heart of Florida and Central Florida Cancer...
LAVA Therapeutics Receives FDA Orphan Drug Designation for LAVA-051 for the Treatment of Chronic Lymphocytic Leukemia
October 15, 2021 07:00 ET
|
Lava Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Oct. 15, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company, today announced that the U.S. Food and...
CORRECTING and REPLACING: LAVA Therapeutics to Present its Bispecific Gamma Delta T Cell Engagers for Treatment of Cancer at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
October 07, 2021 12:36 ET
|
Lava Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by LAVA Therapeutics N.V. (Nasdaq: LVTX), please note that in...
LAVA Therapeutics to Present its Bispecific Gamma Delta T Cell Engagers for Treatment of Cancer at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
October 07, 2021 11:31 ET
|
Lava Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing bispecific gamma...
Florida Cancer Specialists & Research Institute Expands Next Generation Genomic Testing Capabilities to Advance Cancer Care
October 07, 2021 10:10 ET
|
Florida Cancer Specialists & Research Institute
Fort Myers, Fla, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute (FCS) recently expanded its molecular testing capabilities at its state-of-the-art Pathology...